BCL2 and B-cell chronic lymphocytic leukemia: Venetoclax, a drug targeting Bcl-2, is currently approved for the treatment of a refractory form of chronic lymphocytic leukemia [14,15], and other drugs that directly target Bcl-2-family proteins are now in cancer clinical trials [16–18].